Drive R&D strategy and execution for all genomics products and systems across Fluidigm, an innovative leader in cell and tissue analysis powering groundbreaking insights in academic, clinical research, pharma research and biotech.

Consultancy for business strategy, research, product development and operations• Providing hands-on consulting services to three life science and diagnostic startup companies.• Joined LeukoDx’s Scientific Advisory Board, September, 2012• Member, University of California Extension, Medical Devices Certificate Advisory Board• Vice President, R&D, Affymetrix Gene Expression Business Unit, Nov., 2011 – July, 2012 o Multi-year product portfolio planning and execution for $115M/year business. New products launched in April and July 2012. Prepared for multiple product launches in 2013.

Executive Responsibilities: Software, IT, Bioinformatics, Engineering, Molecular Biology, PMO & IP• Product launches: o RapidHIT ID family – sample-to-answer compact platforms for rapid and highly easy-to-use decentralized human DNA forensics. Employs microfluidic-based consumables:o RapidHIT ID3 multiplex system December 2017. RapidHIT ID, Sept. 2015.o RapidLINK - cloud-based software platform for complete, secure and simple management of a geographically distributed network of RapidHIT ID and legacy systems:o RapidLINK II with multiple forensic DNA applications integrating all available legacy instrumentation, November 2017. RapidLINK I, October 2015.o RapidHIT first fully-automated Rapid DNA system for human forensics, Sept. 2013.• Developed products that defined global RapidDNA marketplace. Over $50M revenue generated.• Led collaborations with FBI, Scotland Yard, multiple international regional police & defense forces and political entities to develop marketplace for Rapid DNA systems. • Direct responsibility for large-scale networked metropolitan deployments.• Transitioned R&D organization to ISO 9001 compliance.

Managed 122-person organization in Santa Clara, CA and Bejing, China.EXECUTIVE RESPONSIBILITESo Molecular Biology & Reagent Development, Clinical Applications, Engineering, Applied Bioinformatics Software Development and Program ManagementKEY CORPORATE ACHIEVEMENTSo Conceived & launched company-wide change-management initiative to radically improve product development: Established two of Affymetrix’s four 2010 and 2011 corporate goals, and Industry-dominating clinical product conceived, developed and commercialized on time and budget utilizing new initiative processes. $18M first year revenue. KEY PRODUCT DEVELOPMENT ACHIEVEMENTSo Co-leader (with Sales & Marketing) UCSF/Kaiser Genotyping Consortium. 100,000 patients successfully genotyped in 18 months. Affymetrix’s largest revenue project.o Developed multiple genotyping, copy number and gene expression products. FDA 510(k) submission and approval of Affymetrix’s first gene expression system.o Industry-changing cytogenetics product conceived, developed and commercialized on time and budget. o Built Clinical Applications Development organization enabling Affymetrix to enter the diagnostic marketplace. Products launching in 2012. o Worked with FDA, American College of Medical Genetics and key opinion leaders to define competitive regulatory strategy for a new cytogenetics marketplace.o Initiated and led GeneTitanMC customer care and quality improvement programs. Reduced install errors by 50% and extended mean-time-between failure by 200%.

Guava Technologies is a manufacturer of instruments and reagents for research and clinical flow cytometry, and was acquired by Millipore in March 2009. Managed 51-person organizationEXECUTIVE RESPONSIBILITIESo R&D (California, India & Colorado): biology, engineering and softwareo Operations (California & UK): instrument and reagent manufacturing, quality control, supply chain, logistics and facilities.o Global service & customer support. Offices in CA, UK and India.o Intellectual property strategy and managemento Drove top- and bottom-line growth leading to Millipore acquisition in March 2009:1. Market-leading product portfolio developed and commercialized2. Ten-fold increase in clinical market revenue through:• FDA 510(k) approval for an HIV/AIDS monitoring system, and • Organizational transition to ISO 13485 compliance3. Significantly improved operations efficiency and supply chain effectivenessKEY R&D ACHIEVEMENTSo Identified significant market opportunities for enhanced performance and customer ease of use. Commercialized highly successful next-generation instrument platform.o Doubled research marketplace revenue through introduction of 97 reagent products, 4 new instrument products and multiple software & hardware feature enhancements. KEY OPERATIONS ACHIEVEMENTSo More than doubled overall capacity. Reduced working capital by 54%. Reduced BOMs & doubled first-pass yields: 9pt margin gain. o Planned and completed outsourced manufacturing. Negotiated novel supply agreement to minimize supply chain disruption and cost. Reduced BOM by >15%o Dramatically improved quality and reliability across multiple instrument and wet/chemistry product lines. Improved customer satisfaction and service margin.o Improved facilities: manufacturing shop floor and extensive building improvements. o Re-energized global customer support and field service organizations. Measured and improved customer satisfaction and profitability. Improved revenue 24%.

Managed 22 reportsEXECUTIVE RESPONSIBILITIESo Engineering, software and quality assurance groupso Intellectual property strategy and managementKEY ACHIEVEMENTSo Launched Guava's top-selling instrument platform.o Initiated research programs in software & optics. Product introductions 2007, 2009 & 2011.

Reported to CEORESPONSIBILITIESProduct development group & intellectual property strategy and management.KEY ACHIEVEMENTSo Managed R&D and production for high-margin sensor product family. Product introduction May 2004. > 300 units shipped.o Led design and development of tunable filter subsystems. > 500 units shippedo Led R&D for three subsystems of telecom-grade tunable laser. > 6000 units shipped